Epidermal growth factor receptor blockers for the treatment of ovarian cancer

Morrison, Jo; Thoma, Clemens; Goodall, Richard; Lyons, Thomas J; Gaitskell, Kezia; Wiggans, Alison J; Bryant, Andrew

doi:10.1002/14651858.cd007927.pub4

Cited by 17 publications

(14 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian cancer (OC) is s the seventh most common cancer and a type of gynaecological malignancies, with high mortality in females [1][2][3]. The majority of ovarian cancers (nearly 90%) are originated from epithelial tissues [4,5]. Despite ongoing efforts to find effective treatment methods for OC, the overall survival rate remains less than 30%, which was mainly caused by the difficulty for early diagnosis, and often results in a poor prognosis [6,7].…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

Wang

Yue³

et al. 2019

J Ovarian Res

View full text Add to dashboard Cite

Ovarian cancer (OC) is a type of gynaecological malignancy with high mortality in females. Serous ovarian cancer (SOC) is a distinct subtype of OC with poor early diagnosis. Given the limitations of traditional therapies, such as chemotherapy, targeted treatment is therefore a promising therapy to improve the survival rate of SOC patients. Cyclophilin A (CYPA) is a member of Cyclophilin family and thought to participates in multiple cellular processes such as cell transduction and immune modulation. Recently, various of studies indicated that CYPA has critical impact on cancer progression. CYPA could regulate cell proliferation, invasion, and chemoresistance of multiple types of cancers. However, it is still unclear whether it could affect ovarian cancer. In this study, we demonstrated that CYPA was highly expressed in SOC tissues compared with adjacent tissues. Further, CYPA was significantly associated with clinical stage and lymphnode metastasis of SOC patients. Additionally, data indicated that knockdown of CYPA by its shRNA dramatically reduces migration and invasion capacity of SOC cells in vitro and blocks tumor metastasis in vivo. Our study investigates the involvement of CYPA in the progression and metastasis of SOC, and therefore provides CYPA as a promising therapeutic target for SOC treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

Wang

Yue³

et al. 2019

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…However, within malignant OSE, it begins to support the course of ovarian carcinogenesis by decreasing the expression of genes associated with the stable growth of cells and enhancing the expression of genes associated with oncogenic potential [28]. Regulatory hormones and growth factors which display dichotomous functions in the ovary have provided effective targets for hormone therapies and growth blockers in ovarian cancer treatment [29,30].…”

Section: Ovulationmentioning

confidence: 99%

Factors in Oncogenesis: Viral Infections in Ovarian Cancer

Wilczyński

Paradowska

2020

Cancers

View full text Add to dashboard Cite

Ovarian cancer (OC) is one of the leading causes of cancer death in women, with high-grade serous ovarian cancer (HGSOC) being the most lethal gynecologic malignancy among women. This high fatality rate is the result of diagnosis of a high number of new cases when cancer implants have already spread. The poor prognosis is due to our inadequate understanding of the molecular mechanisms preceding ovarian malignancy. Knowledge about the site of origination has been improved recently by the discovery of tube intraepithelial cancer (TIC), but the potential risk factors are still obscure. Due to high tumoral heterogeneity in OC, the establishment of early stage biomarkers is still underway. Microbial infection may induce or result in chronic inflammatory infection and in the pathogenesis of cancers. Microbiome research has shed light on the relationships between the host and microbiota, as well as the direct roles of host pathogens in cancer development, progression, and drug efficacy. While controversial, the detection of viruses within ovarian malignancies and fallopian tube tissues suggests that these pathogens may play a role in the development of OC. Genomic and proteomic approaches have enhanced the methods for identifying candidates in early screening. This article summarizes the existing knowledge related to the molecular mechanisms that lead to tumorigenesis in the ovary, as well as the viruses detected in OC cases and how they may elevate this process.

show abstract

“…• Little or no difference to survival, either as maintenance treatment after first-line chemotherapy or in association with chemotherapy in recurrent cancer [89].…”

Section: Egf Receptormentioning

confidence: 99%

“… EGF receptor Is associated with less favorable disease outcomes [ 88 ]. • Little or no difference to survival, either as maintenance treatment after first-line chemotherapy or in association with chemotherapy in recurrent cancer [ 89 ]. Abbreviations : CA125 cancer antigen 125, HE4 human epididymis secretory protein 4, VEGF vascular endothelial growth factor, M-CSF macrophage colony stimulating factor, EphA2 ephrin type-A receptor 2, B7-H4 a molecule of B7 family …”

Section: Introductionmentioning

confidence: 99%

Prediction of the treatment response in ovarian cancer: a ctDNA approach

Sharbatoghli

Vafaei

et al. 2020

J Ovarian Res

View full text Add to dashboard Cite

Ovarian cancer is the eighth most commonly occurring cancer in women. Clinically, the limitation of conventional screening and monitoring approaches inhibits high throughput analysis of the tumor molecular markers toward prediction of treatment response. Recently, analysis of liquid biopsies including circulating tumor DNA (ctDNA) open new way toward cancer diagnosis and treatment in a personalized manner in various types of solid tumors. In the case of ovarian carcinoma, growing pre-clinical and clinical studies underscored promising application of ctDNA in diagnosis, prognosis, and prediction of treatment response. In this review, we accumulate and highlight recent molecular findings of ctDNA analysis and its associations with treatment response and patient outcome. Additionally, we discussed the potential application of ctDNA in the personalized treatment of ovarian carcinoma. Graphical abstract ctDNA-monitoring usage during the ovarian cancer treatments procedures.

show abstract

Epidermal growth factor receptor blockers for the treatment of ovarian cancer

Cited by 17 publications

References 84 publications

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

Factors in Oncogenesis: Viral Infections in Ovarian Cancer

Prediction of the treatment response in ovarian cancer: a ctDNA approach

Contact Info

Product

Resources

About